Overview

At a Glance

  • CD34+ cell therapy platform company with an advanced clinical pipeline with two programs with cell therapy “breakthrough” designation
  • Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
  • Multiple potential value creating events in the next 12 months based on development milestones across the pipeline
  • Strong balance sheet; $33.7 million in cash (June 30, 2019) with no debt and cash runway projected through mid-2020
  • Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
Sign up to our e-mail list to receive Caladrius announcements.

Stock Chart

Maximum 30 minute delay for quote.

Investor & Media Contact:


Caladrius Biosciences, Inc.

John D. Menditto
Vice President
Investor Relations & Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com